65 results on '"Fernandez-Barrena, Maite G."'
Search Results
2. FRI-464 Caspases compromise SLU7 and UPF1 stability and nonsensemediated RNA decay activity during hepatocarcinogenesis
3. FRI-555 New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: a human and experimental study
4. Impact of G9a and DNMT1 expression in pancreatic cancer survival: new potential epigenetic therapeutic strategy
5. Therapeutic potential of targeting protein hyper-SUMOylation in cholangiocarcinoma
6. Pediatric liver cancer: Hepatoblastoma and Neddylation post-translational modification
7. Biomarkers of endothelial dysfunction in patients with non-alcoholic fatty liver disease (NAFLD)
8. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma
9. Single-cell RNA sequencing in DIAMOND mice reveals differentially regulated pathways specifically associated with the transition from simple steatosis towards NASH
10. KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor
11. Antitumoral activity of the G9a inhibitor EZM8266 in hepatocellular carcinoma: potential for combination with immune checkpoint inhibitors
12. Supplementary Figure Legend from IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis
13. Supplementary Figures 1 through 6 from IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis
14. Data from IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis
15. Data from IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis
16. Supplementary Figures 1 through 6 from IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis
17. Supplementary Figure Legend from IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis
18. Data from GLI1 Inhibition Promotes Epithelial-to-Mesenchymal Transition in Pancreatic Cancer Cells
19. Data from GLI1 Inhibition Promotes Epithelial-to-Mesenchymal Transition in Pancreatic Cancer Cells
20. Supplementary Methods and Materials, Figures 1-9 from GLI1 Inhibition Promotes Epithelial-to-Mesenchymal Transition in Pancreatic Cancer Cells
21. DNA methylation regulates lncRNAs compromising hepatic identity during hepatocarcinogenesis
22. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
23. Proteomic analysis of bile in the rat thioacetamide model reveals new mechanisms in human cholangiocarcinogenesis
24. The inhibition of the epigenetic efectors DNMT1 and G9a as a potential therapeutic strategy against the non-alcoholic fatty liver development
25. Plasma cell-free DNA methylation as biomarker for hepatocellular carcinoma
26. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumour-stroma crosstalk in experimental models
27. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
28. Epigenetic remodelling in human hepatocellular carcinoma
29. List of Contributors
30. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
31. Dual Targeting of G9a and DNA Methyltransferase‐1 for the Treatment of Experimental Cholangiocarcinoma
32. Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge
33. Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis
34. Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?
35. GLI1/GLI2 functional interplay is required to control Hedgehog/GLI targets gene expression
36. Proteostasis improvement in cystic cholangiocytes alleviates endoplasmic reticulum stress and halts polycystic liver disease
37. SLU7 downregulation potentiates liver damage through hepatic de-differentiation
38. Epigenetic mechanism and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNA methyltransferase 1 for the inhibition of liver fibrosis
39. Dual inhibition of DNA methyltransferase 1 and the histone methyltransferase G9a as a new therapeutic strategy in hepatoblastoma
40. The splicing regulator SLU7 is required for DNMT1 protein stability and DNA methylation maintenance
41. Epigenetic Mechanisms in Hepatic Stellate Cell Activation During Liver Fibrosis and Carcinogenesis
42. THU-064-Identification of new epigenetic targets in hepatic fibrosis
43. PS-043-Dual targeting of G9a and DNM-methyltransferase-1 for the treatment of experimental cholangiocarcinoma
44. THU-468-SLU7 controls genome integrity: New role of truncated SRSF3 proteins
45. Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications
46. MicroRNA‐506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation
47. Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice
48. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration
49. IKBKE Is Required during KRAS-Induced Pancreatic Tumorigenesis
50. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.